Sulfur-Containing Ionizable Lipids for Extrahepatic Nucleic Acid Delivery
Solution Overview
Problem
There is a need for ionizable lipids that offer improved potency, organ-selectivity, and cost-effective manufacturing for the delivery of therapeutic agents or prodrugs, while addressing challenges such as rapid degradation of nucleic acids in plasma and intracellular delivery.
Innovation Solution
Development of sulfur-containing ionizable lipids with specific structures, formulated in delivery vehicles like lipid nanoparticles, which exhibit enhanced extrahepatic organ selectivity and can be efficiently prepared using Claisen technology, enabling higher nucleic acid delivery to tissues like the spleen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional ionizable lipids like MC3 are used for nucleic acid delivery, then formulation efficiency is improved, but manufacturing cost increases due to high nucleic acid requirements
Solution Approach 1:
The patent modifies the chemical structure of ionizable lipids by introducing sulfur-containing functional groups and varying chain lengths/compositions, which changes the physical and chemical parameters of the lipid molecules. This structural parameter change enables the new lipids to achieve superior transfection efficiency with lower nucleic acid dosages, directly resolving the contradiction between formulation efficiency and nucleic acid quantity requirements
Solution Approach 2:
The patent creates composite lipid structures by combining sulfur-containing groups with specific hydrocarbon chains and ionizable head groups. These composite molecular structures exhibit enhanced ability to complex with nucleic acids and facilitate cellular uptake, thereby improving formulation efficiency while reducing the amount of nucleic acid needed for effective delivery
2Manufacturing precision
If sulfur-containing ionizable lipids are used to improve extrahepatic organ selectivity, then delivery precision to target tissues is improved, but manufacturing complexity may increase
Solution Approach 1:
The patent introduces sulfur-containing functional groups at specific positions within the lipid molecule structure, creating local chemical differences that confer organ-selective properties. This local structural modification approach enables precise control over tissue distribution and targeting without requiring complex overall molecular architectures, thus achieving high manufacturing precision while managing complexity
Solution Approach 2:
By systematically varying parameters such as sulfur group position, chain length, and saturation levels in the lipid structure, the patent optimizes organ selectivity for extrahepatic tissues. These parameter adjustments allow fine-tuning of biodistribution properties through relatively straightforward synthetic modifications rather than complex manufacturing processes
3Reliability
If higher potency ionizable lipids are developed to reduce dosing, then therapeutic efficacy is improved, but development and manufacturing costs may increase
Solution Approach 1:
The patent employs systematic parameter optimization of the lipid structure, including sulfur group incorporation, chain length variation, and head group modification, to achieve high potency with ED50 values as low as 0.03. This structured parameter exploration enables identification of cost-effective molecular configurations that deliver superior efficacy without requiring excessively complex or expensive manufacturing processes
Solution Approach 2:
The patent develops lipid structures that can be synthesized through relatively simple and scalable chemical routes, making the high-potency lipids economically viable for large-scale production. By focusing on chemically tractable molecular designs with readily available starting materials and straightforward synthesis pathways, the patent reduces manufacturing costs while maintaining high therapeutic efficacy
Data Source
AI summary
Provided herein are novel sulfur-containing lipids having a structure of Formula A or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acids for use in the targeting of a non-liver organ, tissue or cell. Further provided are methods for making the compounds. (Formula A)